|
1
|
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
|
Nature
|
2005
|
19.56
|
|
2
|
Retracted
Genomic signatures to guide the use of chemotherapeutics.
|
Nat Med
|
2006
|
7.45
|
|
3
|
Retracted
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
|
J Clin Oncol
|
2007
|
5.77
|
|
4
|
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
|
Lancet Oncol
|
2012
|
5.70
|
|
5
|
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
|
Cancer Res
|
2004
|
5.68
|
|
6
|
Common variants at 19p13 are associated with susceptibility to ovarian cancer.
|
Nat Genet
|
2010
|
4.51
|
|
7
|
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
|
Nat Genet
|
2009
|
4.38
|
|
8
|
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
|
Nat Genet
|
2013
|
4.35
|
|
9
|
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
|
Nat Genet
|
2010
|
3.86
|
|
10
|
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
|
Nat Genet
|
2013
|
3.42
|
|
11
|
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
|
J Clin Oncol
|
2005
|
3.31
|
|
12
|
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
|
Clin Cancer Res
|
2005
|
2.98
|
|
13
|
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
|
Clin Cancer Res
|
2004
|
2.96
|
|
14
|
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.
|
J Natl Cancer Inst
|
2014
|
2.40
|
|
15
|
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
|
J Clin Oncol
|
2004
|
2.32
|
|
16
|
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines.
|
Cancer Res
|
2011
|
2.32
|
|
17
|
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
|
Gynecol Oncol
|
2007
|
2.20
|
|
18
|
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
|
Clin Cancer Res
|
2011
|
2.09
|
|
19
|
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.
|
Obstet Gynecol
|
2010
|
1.94
|
|
20
|
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
|
Cancer Res
|
2007
|
1.92
|
|
21
|
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
|
Cancer Prev Res (Phila)
|
2009
|
1.78
|
|
22
|
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
|
Gynecol Oncol
|
2006
|
1.75
|
|
23
|
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.73
|
|
24
|
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
|
Nat Commun
|
2013
|
1.73
|
|
25
|
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
|
Gynecol Oncol
|
2005
|
1.71
|
|
26
|
Gene expression patterns that characterize advanced stage serous ovarian cancers.
|
J Soc Gynecol Investig
|
2004
|
1.68
|
|
27
|
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
|
Gynecol Oncol
|
2008
|
1.65
|
|
28
|
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
|
Gynecol Oncol
|
2013
|
1.61
|
|
29
|
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.
|
Cancer Res
|
2009
|
1.59
|
|
30
|
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.
|
Cancer
|
2003
|
1.56
|
|
31
|
Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.
|
Gynecol Oncol
|
2003
|
1.55
|
|
32
|
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.
|
Cancer Res
|
2003
|
1.54
|
|
33
|
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
|
Cancer
|
2010
|
1.53
|
|
34
|
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk.
|
Hum Mol Genet
|
2013
|
1.52
|
|
35
|
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
|
J Clin Oncol
|
2003
|
1.49
|
|
36
|
Ovarian cancer risk factors in African-American and white women.
|
Am J Epidemiol
|
2009
|
1.49
|
|
37
|
Evaluation of two management strategies for preoperative grade 1 endometrial cancer.
|
Obstet Gynecol
|
2009
|
1.48
|
|
38
|
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".
|
PLoS Genet
|
2010
|
1.47
|
|
39
|
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.
|
Am J Epidemiol
|
2008
|
1.46
|
|
40
|
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.
|
Gynecol Oncol
|
2011
|
1.44
|
|
41
|
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
|
Mol Cancer Res
|
2006
|
1.43
|
|
42
|
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
|
Cancer
|
2011
|
1.43
|
|
43
|
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.
|
Hum Mol Genet
|
2009
|
1.42
|
|
44
|
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
|
Gynecol Oncol
|
2004
|
1.41
|
|
45
|
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
|
J Clin Oncol
|
2006
|
1.41
|
|
46
|
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
|
Nat Commun
|
2013
|
1.36
|
|
47
|
Role of genetic polymorphisms and ovarian cancer susceptibility.
|
Mol Oncol
|
2009
|
1.33
|
|
48
|
Analgesic drug use and risk of ovarian cancer.
|
Epidemiology
|
2006
|
1.33
|
|
49
|
Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.
|
PLoS One
|
2010
|
1.28
|
|
50
|
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
|
Gynecol Oncol
|
2007
|
1.26
|
|
51
|
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
|
Gynecol Oncol
|
2007
|
1.24
|
|
52
|
Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin.
|
Lab Invest
|
2003
|
1.21
|
|
53
|
Cell proliferation and apoptosis in human uterine leiomyomas and myometria.
|
Virchows Arch
|
2002
|
1.20
|
|
54
|
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
|
Clin Cancer Res
|
2003
|
1.19
|
|
55
|
Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
|
Clin Cancer Res
|
2005
|
1.18
|
|
56
|
Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.
|
Int J Cancer
|
2011
|
1.17
|
|
57
|
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
|
Clin Cancer Res
|
2011
|
1.17
|
|
58
|
Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.
|
Cancer Prev Res (Phila)
|
2013
|
1.17
|
|
59
|
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.
|
Nucleic Acids Res
|
2006
|
1.16
|
|
60
|
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2006
|
1.15
|
|
61
|
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.
|
Gynecol Oncol
|
2009
|
1.15
|
|
62
|
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).
|
Cancer Causes Control
|
2002
|
1.14
|
|
63
|
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
|
Int J Gynecol Cancer
|
2012
|
1.14
|
|
64
|
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.14
|
|
65
|
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
|
Clin Cancer Res
|
2003
|
1.12
|
|
66
|
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
|
Cancer Prev Res (Phila)
|
2011
|
1.10
|
|
67
|
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
|
Gynecol Oncol
|
2007
|
1.10
|
|
68
|
Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.
|
Clin Cancer Res
|
2007
|
1.10
|
|
69
|
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.
|
Int J Epidemiol
|
2013
|
1.10
|
|
70
|
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
1.09
|
|
71
|
ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.08
|
|
72
|
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.
|
Genome Res
|
2010
|
1.08
|
|
73
|
Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women.
|
Cancer Causes Control
|
2005
|
1.08
|
|
74
|
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer.
|
Gynecol Oncol
|
2013
|
1.07
|
|
75
|
Predictors of clinical outcomes in the laparoscopic management of adnexal masses.
|
Obstet Gynecol
|
2003
|
1.06
|
|
76
|
The role of PET scanning in the detection of recurrent cervical cancer.
|
Gynecol Oncol
|
2003
|
1.05
|
|
77
|
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.
|
Gynecol Oncol
|
2012
|
1.03
|
|
78
|
Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
1.02
|
|
79
|
Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.
|
Gynecol Oncol
|
2005
|
1.02
|
|
80
|
Expression signatures of TP53 mutations in serous ovarian cancers.
|
BMC Cancer
|
2010
|
1.02
|
|
81
|
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
|
Gynecol Oncol
|
2011
|
1.01
|
|
82
|
Relationship between tamoxifen use and high risk endometrial cancer histologic types.
|
Gynecol Oncol
|
2008
|
1.00
|
|
83
|
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
|
Gynecol Oncol
|
2003
|
0.99
|
|
84
|
Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.
|
Neoplasia
|
2010
|
0.99
|
|
85
|
Projecting the need for gynecologic oncologists for the next 40 years.
|
Obstet Gynecol
|
2010
|
0.99
|
|
86
|
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
|
Hum Genet
|
2013
|
0.99
|
|
87
|
Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
|
Gynecol Oncol
|
2007
|
0.98
|
|
88
|
Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.
|
Gynecol Oncol
|
2007
|
0.98
|
|
89
|
Ovarian cancer risk associated with inherited inflammation-related variants.
|
Cancer Res
|
2012
|
0.98
|
|
90
|
Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta.
|
J Natl Cancer Inst
|
2002
|
0.97
|
|
91
|
High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
|
Clin Cancer Res
|
2003
|
0.97
|
|
92
|
Outcomes in surgical stage I uterine papillary serous carcinoma.
|
Gynecol Oncol
|
2007
|
0.97
|
|
93
|
Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray.
|
Clin Cancer Res
|
2006
|
0.96
|
|
94
|
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
|
Mol Cancer Res
|
2009
|
0.95
|
|
95
|
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
|
Clin Cancer Res
|
2012
|
0.94
|
|
96
|
MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.94
|
|
97
|
Retraction: Genomic signatures to guide the use of chemotherapeutics.
|
Nat Med
|
2011
|
0.94
|
|
98
|
Inherited variants in regulatory T cell genes and outcome of ovarian cancer.
|
PLoS One
|
2013
|
0.93
|
|
99
|
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
|
Int J Cancer
|
2010
|
0.92
|
|
100
|
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2007
|
0.92
|
|
101
|
Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.92
|
|
102
|
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
|
Am J Surg Pathol
|
2013
|
0.92
|
|
103
|
Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.92
|
|
104
|
The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
|
Gynecol Oncol
|
2006
|
0.91
|
|
105
|
Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
|
Cancer Res
|
2005
|
0.91
|
|
106
|
Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation.
|
Gynecol Oncol
|
2011
|
0.91
|
|
107
|
Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.91
|
|
108
|
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
|
J Natl Cancer Inst
|
2015
|
0.90
|
|
109
|
Risk of ovarian cancer and inherited variants in relapse-associated genes.
|
PLoS One
|
2010
|
0.90
|
|
110
|
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.
|
Cancer Res
|
2013
|
0.89
|
|
111
|
Menopausal hormones and risk of ovarian cancer.
|
Am J Obstet Gynecol
|
2005
|
0.89
|
|
112
|
Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.89
|
|
113
|
Specific keynote: genome copy number abnormalities in ovarian cancer.
|
Gynecol Oncol
|
2003
|
0.89
|
|
114
|
Molecular aspects of ovarian cancer.
|
Best Pract Res Clin Obstet Gynaecol
|
2002
|
0.89
|
|
115
|
Epigenetic determinants of ovarian clear cell carcinoma biology.
|
Int J Cancer
|
2014
|
0.89
|
|
116
|
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
|
Cancer Res
|
2004
|
0.88
|
|
117
|
The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.88
|
|
118
|
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
|
Ann Surg Oncol
|
2006
|
0.88
|
|
119
|
Genomic tests for ovarian cancer detection and management.
|
Evid Rep Technol Assess (Full Rep)
|
2006
|
0.88
|
|
120
|
Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.
|
J Soc Gynecol Investig
|
2003
|
0.87
|
|
121
|
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
|
Cancer
|
2011
|
0.87
|
|
122
|
Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.
|
Twin Res Hum Genet
|
2010
|
0.87
|
|
123
|
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.
|
PLoS One
|
2011
|
0.87
|
|
124
|
The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.
|
J Soc Gynecol Investig
|
2006
|
0.87
|
|
125
|
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.
|
Mol Carcinog
|
2010
|
0.86
|
|
126
|
Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens.
|
Cancer Prev Res (Phila)
|
2011
|
0.86
|
|
127
|
No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.86
|
|
128
|
Patient preferences in advanced or recurrent ovarian cancer.
|
Cancer
|
2014
|
0.85
|
|
129
|
High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.
|
Obstet Gynecol
|
2010
|
0.85
|
|
130
|
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women.
|
Gynecol Oncol
|
2012
|
0.85
|
|
131
|
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.
|
Hum Mol Genet
|
2011
|
0.85
|
|
132
|
Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program.
|
JSLS
|
2010
|
0.84
|
|
133
|
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.84
|
|
134
|
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.
|
PLoS One
|
2011
|
0.83
|
|
135
|
Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.
|
Front Oncol
|
2013
|
0.83
|
|
136
|
Targeting slow-proliferating ovarian cancer cells.
|
Int J Cancer
|
2010
|
0.83
|
|
137
|
Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer.
|
Am J Obstet Gynecol
|
2011
|
0.83
|
|
138
|
Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity.
|
Gynecol Oncol
|
2005
|
0.83
|
|
139
|
Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.
|
Ann N Y Acad Sci
|
2003
|
0.83
|
|
140
|
Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
|
Gynecol Oncol
|
2005
|
0.83
|
|
141
|
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
|
Cancer Immunol Res
|
2014
|
0.82
|
|
142
|
Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
|
Gynecol Oncol
|
2011
|
0.81
|
|
143
|
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
|
Int J Clin Oncol
|
2007
|
0.81
|
|
144
|
Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer.
|
Front Oncol
|
2012
|
0.81
|
|
145
|
The role of genetic testing for cancer susceptibility in gynecologic practice.
|
Obstet Gynecol
|
2007
|
0.81
|
|
146
|
Antidepressant medication use [corrected] and risk of ovarian cancer.
|
Obstet Gynecol
|
2005
|
0.80
|
|
147
|
Common variation in Nemo-like kinase is associated with risk of ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.80
|
|
148
|
Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.
|
Obstet Gynecol
|
2016
|
0.80
|
|
149
|
BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
|
Gynecol Oncol
|
2005
|
0.79
|
|
150
|
Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort.
|
Fertil Steril
|
2010
|
0.79
|
|
151
|
Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.
|
Am J Obstet Gynecol
|
2011
|
0.79
|
|
152
|
Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.
|
PLoS One
|
2011
|
0.78
|
|
153
|
Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
|
Int J Hyperthermia
|
2006
|
0.78
|
|
154
|
Minimally invasive surgery for endometrial cancer: the horse is already out of the barn.
|
J Clin Oncol
|
2012
|
0.78
|
|
155
|
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
0.78
|
|
156
|
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.
|
Mol Nutr Food Res
|
2014
|
0.77
|
|
157
|
Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian Carcinoma.
|
Front Genet
|
2012
|
0.76
|
|
158
|
Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability.
|
Cancer Biomark
|
2006
|
0.76
|
|
159
|
Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.
|
Cancer Prev Res (Phila)
|
2013
|
0.76
|
|
160
|
Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?
|
Lancet Oncol
|
2011
|
0.76
|
|
161
|
Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.
|
Nat Genet
|
2015
|
0.75
|
|
162
|
Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci.
|
Cancer Epidemiol Biomarkers Prev
|
2016
|
0.75
|
|
163
|
Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing"
|
Clin Cancer Res
|
2011
|
0.75
|
|
164
|
Microarray analysis of gene expression in gynecologic cancers--still only the beginning.
|
Gynecol Oncol
|
2009
|
0.75
|
|
165
|
Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.
|
Am J Epidemiol
|
2016
|
0.75
|
|
166
|
Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies.
|
Am J Epidemiol
|
2016
|
0.75
|
|
167
|
Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
|
J Clin Oncol
|
2007
|
0.75
|
|
168
|
Stretching the surface epithelium.
|
J Soc Gynecol Investig
|
2004
|
0.75
|
|
169
|
Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.75
|
|
170
|
Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore.
|
Obstet Gynecol
|
2012
|
0.75
|
|
171
|
Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer.
|
Int J Gynecol Pathol
|
2017
|
0.75
|
|
172
|
Scientific innovation--pathway to progress in women's cancer.
|
Gynecol Oncol
|
2008
|
0.75
|
|
173
|
Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence.
|
Am J Epidemiol
|
2017
|
0.75
|
|
174
|
Prevention and early detection of cancer.
|
Gynecol Oncol
|
2011
|
0.75
|
|
175
|
Transcript expression in endometrial cancers from Black and White patients.
|
Gynecol Oncol
|
2013
|
0.75
|